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In 2011, the National Institute for Health and Care Excellence (NICE) revised their guidance on the 10 
timing of intravenous prophylactic antibiotic administration for Caesarean section, advising that 11 
antibiotics should be given prior to skin incision(1). This change has recently been supported by a 12 
Cochrane review which advises administration of antibiotics 60 minutes prior to incision to prevent 13 
maternal postpartum infectious morbidity(2). While it is clearly important that women giving birth 14 
are protected from infection-related complications of Caesarean section, it is also of concern that 15 
nearly 25% of births in the United Kingdom (UK) delivered by Caesarean section will be affected by 16 
this recommendation, which will lead to some 175,000 infants(3) annually being exposed to broad 17 
spectrum antibiotics around the time of birth. NICE recommends the use of prophylactic broad 18 
spectrum antibiotics for women undergoing Caesarean section which are effective against the 19 
microorganisms associated with endometritis, urinary tract and wound infections(1). These antibiotics  20 
rapidly cross the placenta and will reach the baby’s circulation before birth, with an inevitable but 21 
not yet fully characterised influence on newborn microbial colonisation. Previous NICE guidance 22 
advised cord clamping prior to giving mothers antibiotics to prevent such collateral neonatal 23 
antibiotic exposure(4).  24 
 25 
There is increasing evidence for a functional role of gut microbiota in driving immune development 26 
in the newborn and the development of chronic conditions later in life(5). We know that the immune 27 
system both modifies and is modified by our response to pathogens according to the composition of 28 
early microbial colonisation(6), and that the pattern of gut colonisation by microorganisms is 29 
associated with mode of delivery(7). There is also evidence that infants with abnormal microbiota are 30 
at increased risk of diseases such as atopic dermatitis, inflammatory bowel disease and Type 1 31 
diabetes(8, 9). As such, there is growing awareness of the importance of microbes and the immune 32 
system as aetiological agents in human disease(5, 10). 33 
 34 
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The recommendation in the Cochrane review draws on data from 12 high quality trial reports 35 
showing an absolute risk reduction of 2.8% in maternal infectious morbidity (from 8.5%  to 5.7%, 36 
relative risk (RR) 0.57, 95% CI 0.45-0.72) when comparing those receiving antibiotics preoperatively 37 
with those receiving antibiotics after cord clamping. This was due to reductions in clinically 38 
diagnosed endometritis (from 28 to 15 per 1000, RR 0.54, 95% CI 0.54-0.82) and wound infection 39 
(from 41 to 24 per 1000, RR 0.59, 95% CI 0.44-0.81), both of which can be associated with sepsis and 40 
maternal mortality(11), although the vast majority of these infections are mild and respond promptly 41 
to treatment. However, the review fails to consider the effects of broad spectrum antibiotics on the 42 
neonatal microbiota and the potential long-term health sequelae of disrupted microbial colonisation 43 
in the infant. 44 
 45 
Ideally, high quality evidence of immediate benefits to the mother should be weighed against 46 
equally good evidence about any potential risks of long-term harm to the infant. However, to date, 47 
no randomised controlled trials (RCTs) have measured the long-term effects on infants of receiving 48 
intrapartum antibiotics. Such studies are unlikely to be undertaken because of the long duration of 49 
follow up required to measure health outcomes that might not present until years later. Evidence 50 
suggesting an adverse effect of early antibiotic exposure on the infant gut currently comes from 51 
observational studies(5), but the limitations in such studies mean they are less likely to be included in 52 
systematic reviews, upon which NICE guidance is primarily based. The focus on RCTs risks potentially 53 
important long-term infant health outcomes being ignored. 54 
 55 
It is possible to test whether early life exposure to antibiotics affects microbial colonisation of the 56 
gut and other mucosal surfaces in the neonate, and to explore whether antibiotics exposure might 57 
lead to selective survival of microbes with genes conferring antimicrobial resistance, without RCT-58 
level evidence(10). Given that the new guidance will affect such large numbers of infants, we feel it is 59 
important to consider the emerging literature on the role of the microbiota in determining long-term 60 
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infant health. This is part of a wider issue for evidence-based practice whereby high-quality reviews 61 
currently prioritise evidence from studies with strong epidemiological designs, which may only 62 
measure short-term outcomes, over weaker evidence of health consequences that may occur in the 63 
longer term. We acknowledge that there is not yet clear evidence on which to base immediate 64 
changes to clinical practice. Instead, we suggest a more nuanced weighing of evidence is needed, 65 
which gives consideration to study designs capable of assessing long-term outcomes. It might also be 66 
time to update how these reviews are communicated to patients, making clear where certain short-67 
term gains are given precedence in structured reviews over uncertain long-term, and potentially 68 
adverse, health outcomes. 69 
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